Acetaldehyde binding products
The Acetium® lozenge eliminates acetaldehyde from the saliva during smoking. It´s been clinically proven to be also a safe and effective way of quit smoking. .
The International Agency for Research on Cancer (IARC), which forms part of the World Health Organization, has classified acetaldehyde included in and generated endogenously from alcoholic beverages as a Group I human carcinogen. Acetaldehyde belongs to the same risk class as, for example, asbestos and tobacco.
Specific microbes (bacteria and yeasts) in the gastrointestinal tract are the most important source of acetaldehyde exposure to the human body. These microbes produce acetaldehyde from alcohol and, in certain circumstances, from sugar. Unlike the liver, the microbes and the intestinal mucosa cannot remove the acetaldehyde, and due to the effect of alcohol, an abundance of acetaldehyde accumulates in the saliva and elsewhere in the gastrointestinal tract. Acetaldehyde is a substance that accumulates in the body from several sources, continuous exposure to it thereby severely increasing the risk of cancer to various organs.
Acetaldehyde is also the most abundant carcinogen in tobacco smoke, and it readily dissolves into saliva during smoking.
To eliminate the carcinogenic acetaldehyde, Biohit developed Acetium® product line, which is a CE marked Medical Device developed and patented by Biohit Oyj.
The Acetium® capsules are intended for persons with a low-acid (hypochlorhydria) or anacidic stomachs to eliminate acetaldehyde and its risks from the Gastrointestinal tract.
The Acetium® lozenge eliminates acetaldehyde from the saliva during smoking. It´s been clinically proven to be also a safe and effective way of quit smoking.
Acetium® is a CE marked product developed and patented by Biohit Oyj. Read more about Acetium from the Acetium.com.
The diagnostic product range of BIOHIT HealthCare focuses on innovative assays for digestive diseases. It includes the GastroPanel blood test, which is used for the diagnosis of Dyspepsia, Helicobacter pylori infection and identification of high-risk gastritis (e.g. atrophic gastritis) non-invasively from a blood sample, helping to select patients who need Gastroscopy in Primary Care. This routine test for the early detection of gastric pathology helps identify patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD) and deficiencies of vitamin B12, calcium and iron.
In addition to GastroPanel, BIOHIT HealthCare also delivers a multitude of enzyme-linked immunosorbent assay tests (ELISAs), and Endoscopy Quick tests for:
- Inflammatory Bowel Disease
- Lactose intolerance
- Helicobacter pylori infection
- Coeliac disease
- Screening of colorectal cancer
- Faecal Calprotectin
- Microbiota Analysis
Notice! In the USA and Japan for research use only.
Acetaldehyde binding products
An acid-free (achlorhydric) stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer. Acetium® is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid (hypochlorhydria) or anacidic stomachs to eliminate acetaldehyde and its risks from the Gastrointestinal tract.
BIOHIT also develops and manufactures monoclonal antibodies for use in cancer diagnosis and as components for immunoassay kits and research.
Adopting a systems approach, BIOHIT also provides complementary laboratory instruments, such as microplate readers and washers, Immunoassay automates, as well as liquid handling products to support BIOHITs laboratory and ELISA tests.